Loading...
Cash Pay Aesthetics Exposure Will Test Injectable Demand Yet Long Term Potential Remains
AN
AnalystLowTarget
Not Invested
Community Contributor
Published
02 Feb 26
Views
28
02 Feb
US$6.59
AnalystLowTarget's Fair Value
US$10.00
34.1% undervalued intrinsic discount1Y
-31.3%7D
-1.9%1Y
-31.3%7D
-1.9%You can edit this narrative until Feb 3 2:10 PM. Then, changes will post as Updates.
Author's Valuation
US$1034.1% undervalued intrinsic discount
AnalystLowTarget Fair Value